Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 7/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.34 |
| ▸ | USP2 | O75604 | 5/20 | 0.33 |
| ▸ | USP8 | P40818 | 5/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3907629 | 0.93 | NR1I2 (0.33) | PDE2AGPR139 | |
| SCHEMBL3899480 | 0.90 | GPR139 (0.34) | PDE2AACLYGPR139 | |
| SCHEMBL3900169 | 0.89 | CCR2 (0.37) | — | |
| SCHEMBL5728253 | 0.89 | NR1I2 (0.33) | GPR139 | |
| SCHEMBL1890458 | 0.89 | CCKBR (0.33) | GPR139 | |
| SCHEMBL3903821 | 0.89 | NR1I2 (0.33) | GPR139 | |
| SCHEMBL3902491 | 0.88 | KCNA5 (0.38) | — | |
| SCHEMBL3900341 | 0.88 | PDE2A (0.40) | PDE2AMCL1ACLYKDM1A | |
| SCHEMBL3901585 | 0.85 | KCNA5 (0.38) | — | |
| SCHEMBL3896549 | 0.84 | L3MBTL1 (0.38) | ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241759-B2 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | claimed |
| US-7550492-B2 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-23 | — | — | US | disclosed |
| US-20070276016-A1 | BENZO[1,2,5]THIADIAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-29 | — | — | US | disclosed |
| US-7241759-B2 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
| EP-1675837-A2 | BENZO [1,2,5] THIADIAZOLE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005012275-A2 | BENZO [1, 2, 5] THIADIAZOLE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
| US-20040224983-A1 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276016-A1 | BENZO[1,2,5]THIADIAZOLE COMPOUNDS | CCKBR, CCKAR, GIPR | PDE2A 2948/4885MCL1 1290/4885USP2 1084/4885 |
| US-20040224983-A1 | Benzo[1,2,5]thiadiazole compounds | CCKBR, CCKAR, BRSK2 | PDE2A 2126/4885MCL1 1352/4885USP2 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.